BRCA2 and ovarian cancer: Without risk-reducing mastectomy, the risk of breast cancer in BRCA1 and BRCA2 mutation carriers is approximately 70%.[25] The NCCN recommends risk-reducing tubo-oophorectomy for women with the BRCA2 mutation (aged 40‐45 years), as it can significantly reduce the incidence of ovarian cancer.[31]